Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 281

1.

3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.

Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D, Sakr WA.

Cancer Res. 2009 May 15;69(10):4468-75. doi: 10.1158/0008-5472.CAN-08-4423. Epub 2009 May 12.

3.

Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.

Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A.

Mol Cancer Ther. 2007 Oct;6(10):2757-65. Epub 2007 Oct 3.

4.
6.

In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.

Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH.

Cancer Res. 2007 Apr 15;67(8):3818-26.

7.

3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin.

Bhatnagar N, Li X, Chen Y, Zhou X, Garrett SH, Guo B.

Cancer Prev Res (Phila). 2009 Jun;2(6):581-9. doi: 10.1158/1940-6207.CAPR-08-0142. Epub 2009 May 26.

8.

Survivin mediates resistance to antiandrogen therapy in prostate cancer.

Zhang M, Latham DE, Delaney MA, Chakravarti A.

Oncogene. 2005 Apr 7;24(15):2474-82.

PMID:
15735703
9.

Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.

Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA, Uslu R.

J Exp Clin Cancer Res. 2008 Sep 12;27:37. doi: 10.1186/1756-9966-27-37.

10.

Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells.

Chinnakannu K, Chen D, Li Y, Wang Z, Dou QP, Reddy GP, Sarkar FH.

J Cell Physiol. 2009 Apr;219(1):94-9. doi: 10.1002/jcp.21650.

11.

Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.

Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU, Chakravarti A.

Prostate. 2005 Aug 1;64(3):293-302.

PMID:
15754318
12.

B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer.

Singh-Gupta V, Banerjee S, Yunker CK, Rakowski JT, Joiner MC, Konski AA, Sarkar FH, Hillman GG.

Cancer Lett. 2012 May 1;318(1):86-92. doi: 10.1016/j.canlet.2011.12.006. Epub 2011 Dec 9.

13.

Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.

Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP, Sarkar FH.

J Biol Chem. 2007 Jul 20;282(29):21542-50. Epub 2007 May 23. Erratum in: J Biol Chem. 2013 Nov 29;288(48):34755.

14.

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M.

Cancer Res. 2007 Sep 1;67(17):8014-21. Erratum in: Cancer Res. 2012 Aug 1;72(15):3886. Mori, Masamichi [added]; Amino, Nobuaki [added]; Hatakeyama, Shinji [added];Minematsu, Tsuyoshi [removed]; Shirasuna, Kenna[removed].

16.
17.

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B.

Clin Cancer Res. 2006 Sep 15;12(18):5578-86.

18.

BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis.

Seo SI, Gera L, Zhau HE, Qian WP, Iqbal S, Johnson NA, Zhang S, Zayzafoon M, Stewart J, Wang R, Chung LW, Wu D.

Clin Cancer Res. 2008 Oct 1;14(19):6198-206. doi: 10.1158/1078-0432.CCR-08-1023.

19.

Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.

Pennati M, Binda M, Colella G, Zoppe' M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N.

Oncogene. 2004 Jan 15;23(2):386-94.

PMID:
14724567
Items per page

Supplemental Content

Write to the Help Desk